SemBioSys - Personal Care

By: Sembiosys  09-12-2011
Keywords: personal care, Pharmaceutical Products

The Problem

There is a high demand for all-natural ingredients for the personal care industry that perform as well, if not better than current synthetic ingredients.

The Solution

SemBioSys has developed an all-natural process to extract oilbodies (oleosomes) from safflower seeds resulting in a base emulsion with superior hydration, skin conditioning and moisturization properties compared to traditional ingredients such as petrolatum or chemical and animal byproducts.

What We Have Accomplished

Burt's Bees became Botaneco's first international brand customer in January 2008, launching two body washes and a hand soap in North America containing Hydresia™.

SemBioSys currently holds a 9.5 per cent interest in Advitech, Botaneco's parent company.

What We Are Working On

Beyond the benefits as a personal care product ingredient, oilbodies hold the potential to act as a carrier and delivery system for pharmaceutical products. Botaneco's strategy is to leverage the commercialization of Hydresia™ to enter into the over-the-counter (OTC) and topical pharmaceutical markets with oleosomes.

Keywords: personal care, Pharmaceutical Products

Contact Sembiosys

Email - none provided

Print this page

Other products and services from Sembiosys


SemBioSys - In Development

We have also developed an extraction process that we believe will allow for the production of chymosin in plants at significantly lower costs than current production systems. We have chosen to work on products for which the inherent benefits of our technology, including scalability and economics, enable them to be commercially viable.


SemBioSys - Diabetes

We believe our plant-made insulin will offer dramatic reductions in capital and operating costs and provide an accessible source of insulin to meet this exploding demand. Discussions with the US Food and Drug Administration have confirmed that safflower-produced insulin is eligible to follow a shortened drug approval process.


SemBioSys - Technology

Our technology is built on two basic capabilities: the use of genetic engineering to attach high-value proteins to (the structures used by seeds to store oil); and extraction of oilbodies from seeds in a cost-effective manner. For the production of high-value proteins, we believe that our plant technology is unique among transgenic systems as it addresses both production and purification challenges.


SemBioSys - Heart Attack and Stroke

Cardiovascular diseases, including heart attack and stroke, are the leading causes of mortality in developed nations and by 2010, are projected to become the leading cause of mortality worldwide. Apo AI is the major protein associated with high density lipoprotein, or "good cholesterol", whose function is to remove excess cholesterol from arteries.


SemBioSys - Overview

The same advantages that drive our pharmaceutical opportunities also apply to our non-pharmaceutical products, which include topical ingredients that are delivering innovation and value for personal care producers, nutritional oils for use in a variety of consumer goods, and applications for agricultural biotechnology.